Cannabis Bioscience International Holdings (CBIH) Cost of Revenue (2022 - 2026)

Cannabis Bioscience International Holdings has disclosed Cost of Revenue across 5 years of filings, most recently posting $3045.0 for Q1 2026.

• Cost of Revenue for Q1 2026 came in at $3045.0, down 84.3% year-over-year; the trailing twelve-month figure through Feb 2026 was $26233.0 (down 42.27% YoY), and the FY2025 annual result was $40106.0, down 12.05% from the prior year.
• Cost of Revenue came in at $3045.0 for Q1 2026 at Cannabis Bioscience International Holdings, down from $10500.0 in the prior quarter.
• In the past five years, Cost of Revenue ranged from a high of $24120.0 in Q1 2023 to a low of $3045.0 in Q1 2026.
• The 5-year median for Cost of Revenue is $9349.0 (2023), against an average of $11043.6.
• Across the five-year window, Cost of Revenue jumped 112.86% in 2023 and sank 84.3% in 2026, its largest moves.
• Cannabis Bioscience International Holdings' Cost of Revenue stood at $7090.0 in 2022, then surged by 112.86% to $15092.0 in 2023, then tumbled by 48.3% to $7803.0 in 2024, then soared by 34.56% to $10500.0 in 2025, then tumbled by 71.0% to $3045.0 in 2026.
• The last three Cost of Revenue figures came in at $3045.0 (Q1 2026), $10500.0 (Q4 2025), and $8143.0 (Q3 2025), per Business Quant data.